StockData
Evaxion A/S logo

Evaxion A/S (EVAX) stock

EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.54−0.24 (-8.63%)

Close on Nov 18, 2026Market cap $21.18MP/E –Yield –

Evaxion A/S net income

Net income is the profit left for shareholders after every expense, interest and tax.

Evaxion A/S's net income for the twelve months ending Jun 30, 2022 was -$24.18M. For fiscal 2025 it was -$7.71M. The highest annual figure on record is -$5.54M in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.71M–
FY2024Dec 31, 2024-$10.57M–
FY2023Dec 31, 2023-$22.13M–
FY2022Dec 31, 2022-$23.17M–
FY2021Dec 31, 2021-$24.53M–
FY2020Dec 31, 2020-$15.02M–
FY2019Dec 31, 2019-$11.20M–
FY2018Dec 31, 2018-$5.54M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.73M–
Q2 FY2025Jun 30, 2025-$4.83M–
Q2 FY2024Jun 30, 2024-$6.20M–
Q2 FY2023Jun 30, 2023-$5.68M–
Q2 FY2022Jun 30, 2022-$4.77M–
Q1 FY2022Mar 31, 2022-$5.79M–
Q4 FY2021Dec 31, 2021-$8.37M–
Q3 FY2021Sep 30, 2021-$5.25M–
Q2 FY2021Jun 30, 2021-$6.82M–
Q1 FY2021Mar 31, 2021-$4.09M–
Q4 FY2020Dec 31, 2020-$4.27M–
Q3 FY2020Sep 30, 2020-$4.01M–
Q2 FY2020Jun 30, 2020-$3.64M–
Q1 FY2020Mar 31, 2020-$3.10M–

More Evaxion A/S figures

See a number that looks wrong?